KNSA Stock Forecast & Price Target

Kiniksa Pharmaceuticals is viewed positively because Arcalyst is delivering strong commercial execution, with 1Q26 revenue of $214.3MM, up 56% y/y and 6% q/q, while management lifted FY26 guidance to $930–945MM from $900–920MM. Growth is being supported by more than 4,550 cumulative prescribers, roughly 50% repeat-prescriber contribution, about 20% of patients starting at first recurrence, and only about 18% of the estimated 14,000 multiple-recurrence RP population currently on therapy, leaving substantial runway. The company is also cash flow positive with $468.1MM in cash, and its pipeline—especially KPL-387 with Ph 2 dose-focusing data expected in 2H26 and Ph 3 initiation by YE26—adds long-term upside while extending its IL-1 leadership.

Kiniksa Pharmaceuticals is facing a bearish setup because its valuation depends heavily on Arcalyst gaining strong commercial traction in recurrent pericarditis, yet adoption could prove weaker than expected. Its outlook is also challenged by the possibility that competing products emerge with better efficacy or market positioning, which could erode demand and compress its long-term revenue opportunity. In addition, regulatory and commercial uncertainty around whether biologics for rare diseases can sustain premium pricing at commercialization adds another layer of fundamental risk to profitability and valuation.